Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
Published Date: 23 Apr 2023
According to the study, prolonged exposure to nitrogen dioxide, particulate matter PM2.5, and nitrogen oxide may raise the risk of dementia.
Read Full NewsPain that interferes with daily functioning is associated with higher odds of frailty and its progression in adult survivors of childhood cancer.
Cancer care is becoming too complex for any one clinician to track alone, making AI an increasingly valuable tool in modern oncology.
New data with longer-term follow-up suggest that PSA screening probably lowers prostate cancer mortality — but experts stress the gains are modest and come with risk for overdiagnosis.
The CAPItello-281 trial reported a 19% improvement in radiographic progression-free survival.
1.
The Cherenkov color image shows the possibility of improving the quality of radiation therapy.
2.
The Benefits of Exercise for Substance Use Disorders.
3.
PET-CT is better than contrast-enhanced CT as a predictor of survival in patients with metastatic breast cancer
4.
Glioblastoma treatment breakthrough shows promise
5.
NP-Led Outreach Ups Cancer Screening in Rural Women Veterans
1.
Harnessing Snake Venom in Hematology: From Toxins to Life-Saving Therapeutics
2.
Beyond the Blood: Expanding CAR T-Cell Therapy to Solid Tumors- A New Era of Precision Oncology
3.
Case Study: Genomic Medicine in Precision Oncology
4.
Unlocking the Mystery of Leukemia: Exploring New Treatments and Hope for Patients
5.
Advanced Directions in Oncology and Quality Improvement
1.
Asian Symposium on Advancement in Hematology and Oncology
2.
Asian Symposium on Advancement in Hematology and Oncology
3.
International Cancer Conference
4.
Asian Symposium on Advancement in Hematology and Oncology
5.
International Lung Cancer Congress®
1.
From Relapse to Remission Mapping the Treatment Journey in Adult R R B Cell ALL The Critical Goal of MRD
2.
Targeting Oncologic Drivers with Dacomitinib: A New Approach to Lung Cancer Treatment
3.
A Comprehensive Guide to First Line Management of ALK Positive Lung Cancer - Part III
4.
Revolutionizing Treatment of ALK Rearranged NSCLC with Lorlatinib - Part I
5.
Untangling The Best Treatment Approaches For ALK Positive Lung Cancer - Part VI
Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
To get started please enter your email ID
Join to enhance your clinical skills and gain specialized in-depth medical knowledge